Cyclosporine In Klarity

Drug overview for CYCLOSPORINE IN KLARITY (cyclosporine/chondroitin sulfate a):

Generic name: cyclosporine/chondroitin sulfate A
Drug class: Ophthalmic - Anti-Inflammatory, Immunomodulators
Therapeutic class: Ophthalmic Agents

Cyclosporine is a systemic immunosuppressive agent that appears to act as a partial immunomodulator with anti-inflammatory effects after ophthalmic administration.

No enhanced Uses information available for this drug.

DRUG IMAGES

No Image Available

The following indications for CYCLOSPORINE IN KLARITY (cyclosporine/chondroitin sulfate a) have been approved by the FDA:

Indications:
None.

Professional Synonyms:
None.

Moderate List
No disease contraindications

The following adverse reaction information is available for CYCLOSPORINE IN KLARITY (cyclosporine/chondroitin sulfate a):

Overview
Severe
Less Severe

Adverse reaction overview.

The most common adverse effect of cyclosporine ophthalmic emulsion is ocular burning, which occurred in approximately 17% of patients who received the drug in clinical trials. Other adverse effects occurring in 1-5% of patients receiving cyclosporine included conjunctival hyperemia, discharge, epiphora, ocular pain, foreign body sensation, pruritus, stinging, and visual disturbance (e.g., blurring). In clinical trials, no increase in bacterial or fungal ocular infections was reported following administration of cyclosporine ophthalmic emulsion.

There are 1 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Bacterial keratitis

There are 16 less severe adverse reactions.

More Frequent	Less Frequent
Ocular irritation Ocular pain	Blurred vision Conjunctival hyperemia Cough Eye tearing Eyelid edema Headache disorder Ocular discharge Ocular redness Visual changes

Rare/Very Rare
Blepharitis Foreign body sensation of eye Herpes zoster Ocular itching Upper respiratory infection

The following precautions are available for CYCLOSPORINE IN KLARITY (cyclosporine/chondroitin sulfate a):

Pediatric
Pregnant
Lactation
Geriatric

Safety and efficacy not established in children younger than 16 years of age.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

Category C. (See Users Guide.)

It is not known whether cyclosporine is distributed into milk following topical application to the eye; however, cyclosporine is distributed into milk following systemic administration. Although blood cyclosporine concentrations are undetectable after ophthalmic administration of cyclosporine 0.05% emulsion, caution is advised if cyclosporine ophthalmic emulsion is administered in nursing women.

No substantial differences in safety and efficacy relative to younger adults.